One possibility is that CLOCK expression in ALL patients is more sensitive to therapy or the other possibility is that CLOCK expression returning to pre-disease levels could be a potential biomarker for either treatment efficacy or as a read-out for normal circadian activity in ALL patients following treatment. The gene discussed is CLOCK; the disease is acute lymphoblastic leukemia.